|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014653,
umls-concept:C0178602,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0246415,
umls-concept:C0449445,
umls-concept:C0450442,
umls-concept:C0560187,
umls-concept:C0600688,
umls-concept:C0679622,
umls-concept:C1140680,
umls-concept:C1257890,
umls-concept:C1556094,
umls-concept:C2603343
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
1999-6-24
|
|
pubmed:abstractText |
Small patient numbers in phase I trials may result in a safe but ineffective dose being recommended for phase II trials. A phase II dose escalation study may identify a dose that is both safe and effective. The Japanese phase I recommended dose of 60 mg/m2 of docetaxel (Taxotere) had been ineffective in phase II trials in ovarian carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:FujiwaraKK,
pubmed-author:HirabayashiKK,
pubmed-author:KohnoII,
pubmed-author:NodaKK,
pubmed-author:OgitaSS,
pubmed-author:OhashiYY,
pubmed-author:SasakiYY,
pubmed-author:TaguchiTT,
pubmed-author:TanakaKK,
pubmed-author:TerashimaYY,
pubmed-author:TsunematsuRR,
pubmed-author:YakushijiMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
639-44
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10216469-Adolescent,
pubmed-meshheading:10216469-Adult,
pubmed-meshheading:10216469-Aged,
pubmed-meshheading:10216469-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10216469-Carcinoma,
pubmed-meshheading:10216469-Carcinoma, Endometrioid,
pubmed-meshheading:10216469-Clinical Trials, Phase II as Topic,
pubmed-meshheading:10216469-Cystadenocarcinoma, Serous,
pubmed-meshheading:10216469-Dose-Response Relationship, Drug,
pubmed-meshheading:10216469-Female,
pubmed-meshheading:10216469-Humans,
pubmed-meshheading:10216469-Infusions, Intravenous,
pubmed-meshheading:10216469-Japan,
pubmed-meshheading:10216469-Middle Aged,
pubmed-meshheading:10216469-Ovarian Neoplasms,
pubmed-meshheading:10216469-Paclitaxel,
pubmed-meshheading:10216469-Remission Induction,
pubmed-meshheading:10216469-Taxoids,
pubmed-meshheading:10216469-Treatment Outcome
|
|
pubmed:articleTitle |
Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynaecology, Kawasaki Medical School, Kurashiki City, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
